- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Biomarker, Trial completion date, Trial primary completion date, Surgery: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Apr 11, 2024 P3, N=3610, Active, not recruiting, Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Mar 2024 --> Sep 2024
- |||||||||| Trial completion date, Metastases: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - Apr 4, 2024
P2, N=349, Active, not recruiting,
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion date: Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (clinicaltrials.gov) - Mar 25, 2024 P3, N=50, Active, not recruiting,
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion date, Surgery: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Mar 12, 2024 P2, N=454, Active, not recruiting,
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion date: ECOG-ACRIN 5103: Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (clinicaltrials.gov) - Mar 12, 2024 P3, N=4994, Active, not recruiting,
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion date, Surgery, Metastases: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 12, 2024 P2, N=29, Active, not recruiting,
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion date, Metastases: Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 12, 2024 P3, N=403, Active, not recruiting,
- |||||||||| Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma (clinicaltrials.gov) - Feb 20, 2024
P2/3, N=101, Completed, Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Mar 2024 --> Sep 2024 Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2023
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Biomarker, Trial completion date, Trial primary completion date, Surgery: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Dec 19, 2023 P3, N=3610, Active, not recruiting, Trial completion date: Mar 2024 --> Jan 2025 Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion date, Surgery: Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery (clinicaltrials.gov) - Nov 7, 2023 P3, N=1501, Active, not recruiting, Not yet recruiting --> Recruiting Trial completion date: Oct 2023 --> Oct 2024
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion date, Combination therapy, Metastases: Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (clinicaltrials.gov) - Jul 20, 2023 P3, N=692, Active, not recruiting, Trial completion date: Dec 2022 --> Jul 2024 Trial completion date: Jun 2023 --> Jun 2024
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Biomarker, Trial completion date, Trial primary completion date, Surgery: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Apr 27, 2023 P3, N=3610, Active, not recruiting, Recruiting --> Suspended Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| Enrollment change, Mismatch repair, IO biomarker, Metastases: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (clinicaltrials.gov) - Mar 31, 2023
P3, N=120, Recruiting, Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 N=231 --> 120
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Biomarker, Trial completion date, Trial primary completion date, Surgery: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Jul 19, 2022 P3, N=3610, Active, not recruiting, The safety profile of CT-P16 was also similar to that of BV. Trial completion date: Jun 2022 --> Oct 2022 | Trial primary completion date: Jun 2022 --> Oct 2022
- |||||||||| Trial completion date, Trial primary completion date, Mismatch repair, IO biomarker, Metastases: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (clinicaltrials.gov) - Apr 13, 2022
P3, N=231, Recruiting, Recruiting --> Suspended Trial completion date: Apr 2022 --> Nov 2024 | Trial primary completion date: Apr 2022 --> Nov 2024
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Biomarker, Trial completion date, Trial primary completion date, Surgery: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Mar 10, 2022 P3, N=3610, Active, not recruiting, Trial completion date: Apr 2022 --> Nov 2024 | Trial primary completion date: Apr 2022 --> Nov 2024 Trial completion date: Feb 2022 --> Jun 2022 | Trial primary completion date: Feb 2022 --> Jun 2022
|